Trials / Terminated
TerminatedNCT02847702
A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo Controlled and Active-controlled, Parallel-group Study Evaluating the Analgesic Efficacy and Safety of VM902A in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Purdue Pharma LP · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of VM902A twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VM902A 200-mg Capsules | Taken orally with food twice daily |
| DRUG | VM902A 400-mg Capsules | Taken orally with food twice daily |
| DRUG | Naproxen 500-mg Capsules | Taken orally with food twice daily |
| DRUG | Placebo | Capsules to match VM902A and/or naproxen taken orally with food twice daily |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2016-11-22
- Completion
- 2016-11-22
- First posted
- 2016-07-28
- Last updated
- 2017-11-22
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02847702. Inclusion in this directory is not an endorsement.